Australian Pharmaceuticals Industry Data Card 2014

Downloads

This information is also available in the following format/s:

Australian Pharmaceutical Industry Overview

The Australian Pharmaceutical industry is a major high tech industry, with exports of $3.89 billion in 2012-13. The industry employed 15,463 people in manufacturing and the manufacturing sector spent $404 million on product manufacturing R&D in 2011-12. In 2012-13, the pharmaceuticals industry received $7.1 billion from the Pharmaceutical Benefits Scheme (PBS) sales.

Pharmaceutical Industry Turnover in Australia

This graph shows the turnover of the whole pharmaceuticals industry (not only pharmaceutical industry manufacturing) in Australia. It shows that pharmaceuticals industry turnover has increased almost 50% in the last decade, from $16.1 billion in 2003-04 to $23.4 billion in 2012-2013.

Text description of the Pharmaceutical Industry Turnover in Australia graph

The turnover of the whole pharmaceuticals industry (not only pharmaceutical industry manufacturing sector) in Australia was:

  • 2003-04 had $16.1 billion in turnover;
  • 2004-05 had $17.8 billion in turnover;
  • 2005-06 had $20.4 billion in turnover;
  • 2006-07 had $20.2 billion in turnover;
  • 2007-08 had $20.7 billion in turnover;
  • 2008-09 had $21.4 billion in turnover;
  • 2009-10 had $23.1 billion in turnover;
  • 2010-11 had $22.9 billion in turnover;
  • 2011-12 had $23.4 billion in turnover; and
  • 2012-13 had $23.4 billion in turnover.

Source: IBS World, Pharmaceuticals Product Manufacturing in Australia, December 2013. ABS Cat. No. 5368, International Trade in Goods and Services Australia. ABS Cat. No. 8624. Retail and Wholesale Industry.

Pharmaceutical Exports from Australia

This graph shows the total and the percentage of annual growth in pharmaceuticals exports from Australia. It shows that total pharmaceutical exports have decreased to $3.89 billion in 2012-13 from $4.06 billion in 2011-12.

Text description of the Pharmaceutical Exports from Australia graph

Total pharmaceutical exports and annual growth were:

  • 2008-09 increased 2.2 per cent to $4.03 billion in exports;
  • 2009-10 increased 2.2 per cent to $4.12 billion in exports;
  • 2010-11 decreased 7.9 per cent to $3.82 billion in exports;
  • 2011-12 increased 5.9 per cent to $4.06 billion in exports; and
  • 2012-13 decreased 4.4 per cent to $3.89 billion in exports.

Sources: ABS Cat. No. 5368, International Trade in Goods and Services Australia (includes complementary and over the counter medicines.)

Key Statistics: Pharmaceutical Industry in Australia

Selected Key statistics 2006-07 2007-08 2008-09 2009-10 2010-11 2011-12 2012-13
Exports ($b) 3.760 3.944 4.030 4.122 3.819 4.058 3.888
Imports ($b) 7.810 7.984 9.075 9.201 10.089 10.679 10.508
 

Key Statistics: Pharmaceutical Manufacturing in Australia

Selected key statistics 2008-09 2009-10 2010-11 2011-12
Employment at end of June (no.) 14,970 15,074 15,429 16,465
Industry Value Add ($b) 2.53 2.84 2.65 2.91

Sources: ABS Cat. No. 8155, Australian Industry. ABS Cat. No. 8159 Experimental Estimates for the Manufacturing Industry. ANZSIC Class 184. Note: $AUD in current price.

Pharmaceutical Manufacturing BERD in Australia

This graph shows total business expenditure on research and development (BERD) in pharmaceutical manufacturing and compares BERD in pharmaceutical manufacturing to total manufacturing BERD. BERD spend on pharmaceutical manufacturing has increased to $404 million (2012-13) from $379 million in 2010-11, and pharmaceutical manufacturing was 9.0% of the total manufacturing BERD for 2012-13.

Text description of the Pharmaceutical Manufacturing BERD in Australia graph

BERD spend in pharmaceutical manufacturing was:

  • 2005-06 pharmaceutical manufacturing spend was $249 million;
  • 2006-07 pharmaceutical manufacturing spend was $288 million;
  • 2007-08 pharmaceutical manufacturing s spend was $319 million;
  • 2008-09 pharmaceutical manufacturing spend was $410 million;
  • 2009-10 pharmaceutical manufacturing spend was $384 million;
  • 2010-11 pharmaceutical manufacturing spend was $379 million; and
  • 2011-12 pharmaceutical manufacturing spend was $404 million.

Pharmaceutical manufacturing input to total manufacturing BERD:

  • 2005-06 was 6.7 per cent;
  • 2006-07 was 7.5 per cent;
  • 2007-08 was 7.3 per cent;
  • 2008-09 was 9.3 per cent;
  • 2009-10 was 9.0 per cent;
  • 2010-11 was 7.9 per cent; and
  • 2011-12 was 9.0 per cent.

Note: The Australian Pharmaceuticals Industry Data Card 2013 produced by the Department reported pharmaceutical BERD by socio-economic objective. This data is no longer available from the ABS. The current graph depicts BERD by industry class in pharmaceutical manufacturing.

Source: ABS Cat. No. 8104.0. Research and Experimental Development, Businesses, Australia. ANZSIC Class 184. BERD: Business Expenditure in R&D. Note: The Australian Pharmaceuticals Industry Data Card 2013 produced by the Department reported pharmaceutical BERD by socio-economic objective. This data is no longer available from the ABS. The current graph depicts BERD by Industry Class in pharmaceutical manufacturing.

Highest PBS Suppliers by Market Share (Scripts), 2012-13

This chart shows the top ten pharmaceuticals companies that supply the highest value of Pharmaceutical Benefits Scheme (PBS) scripts by market share in 2012-13. 

Text description of the Highest PBS Suppliers by Market Share (Scripts), 2012-13 graph

The market share of the top ten was:

  • Alphapharm with 13 per cent;
  • AstraZeneca with 11 per cent;
  • Apotex with 9 per cent;
  • Pfizer with 9 per cent;
  • Aspen Pharmacare with 8 per cent;
  • sanofi-aventis with 7 per cent;
  • GlaxoSmithKline with 5 per cent;
  • Merck Sharp & Dohme with 4 per cent;
  • Sandoz with 4 per cent;
  • Boehringer Ingelheim with 3 per cent; and
  • 27 per cent of the market share was held by companies outside the top ten.

Source: Expenditure and prescriptions twelve months to 30 June 2013 (Department of Health).

Disclaimer: This report is not meant to constitute professional advice and any persons should seek competent professional advice. The Australian Government accepts no liability whatsoever, including for negligence, for any loss to any person resulting from the use of this material. Unless indicated, all figures are in Australian Dollars.

Contact us

For enquiries regarding this website or further information on the pharmaceuticals industry pleases contact:

Health Technologies Section  

Advanced Technologies Branch

Department of Industry, Innovation and Science  

GPO Box 9839

Canberra ACT 2601

AUSTRALIA

Email: pharmaceutical@industry.gov.au

Share this Page